Brilinta
E505483
P2Y12 receptor antagonist
antiplatelet medication
pharmaceutical drug
platelet aggregation inhibitor
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Brilinta canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248764 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Brilinta Context triple: [AstraZeneca, notableProduct, Brilinta]
-
A.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
B.
apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
-
C.
dabigatran
Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
-
D.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Brilinta Target entity description: Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
A.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
B.
apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
-
C.
dabigatran
Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
-
D.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
P2Y12 receptor antagonist
ⓘ
antiplatelet medication ⓘ pharmaceutical drug ⓘ platelet aggregation inhibitor ⓘ |
| affectsBiologicalProcess | platelet aggregation ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| commonAdverseEffect |
bleeding
ⓘ
bruising ⓘ dyspnea ⓘ epistaxis ⓘ |
| contraindicatedIn |
active pathological bleeding
ⓘ
history of intracranial hemorrhage ⓘ |
| contraindicatedWith |
strong CYP3A4 inducers
ⓘ
strong CYP3A4 inhibitors ⓘ |
| developedBy | AstraZeneca NERFINISHED ⓘ |
| firstApprovedYearUS | 2011 ⓘ |
| hasActiveIngredient | ticagrelor NERFINISHED ⓘ |
| hasAdministrationFrequency | twice daily ⓘ |
| hasATCCode | B01AC24 ⓘ |
| hasBlackBoxWarning | risk of bleeding ⓘ |
| hasDosageForm | oral tablet ⓘ |
| hasDrugClass |
P2Y12 inhibitor
ⓘ
antiplatelet agent ⓘ platelet aggregation inhibitor ⓘ |
| hasGenericName | ticagrelor NERFINISHED ⓘ |
| hasHalfLife |
approximately 7 hours for ticagrelor
ⓘ
approximately 9 hours for active metabolite ⓘ |
| hasMechanismOfAction | reversible inhibition of P2Y12 ADP receptor on platelets ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStrength |
60 mg tablet
ⓘ
90 mg tablet ⓘ |
| indicatedFor |
ST-elevation myocardial infarction
ⓘ
acute coronary syndrome ⓘ history of myocardial infarction ⓘ non–ST-elevation myocardial infarction ⓘ reduction of cardiovascular death ⓘ reduction of heart attack risk ⓘ reduction of stroke risk ⓘ unstable angina ⓘ |
| isPrescriptionOnly | true ⓘ |
| marketedAs |
Brilique
NERFINISHED
ⓘ
Possia NERFINISHED ⓘ |
| metabolizedBy |
CYP3A4
ⓘ
CYP3A5 NERFINISHED ⓘ |
| pregnancyCategoryUS | not assigned (use only if clearly needed) ⓘ |
| reduces | platelet activation ⓘ |
| requiresCoAdministration | low-dose aspirin in most indications ⓘ |
| usedWith | aspirin ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Brilinta Description of subject: Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.